Australia's largest stock trading and investment forum Australia's #1 stock forum

SPA

Click for more information

0.00%

2.2¢ spacetalk ltd

Ann: Spacetalk launches B2B2C channel for LIFE seniors device, page-9

First 9 Last

Share
Profile

Follow
Bundy_Too

4,510 Posts.

365

19/04/21

10:59

Post #: 52560116
Share

Originally posted by cad1llac ↑

Agree @schura.

Will be interesting to see how this strategy translates across UK, US and other markets, though it shouldn't take long for the company to work out what taxpayer support is available in other territories. It's obviously important we are able to sell each of our products across multiple markets to create necessary scale and to build a global user base.

Also worth pointing out that it isn't clear how the 40% drop in price impacts profit margins, and at what point the company reaches breakeven and is able to start building free cash flow. At the reduced pricing, the company needs to generate over 160% the volume to generate the same revenue. If Life sales have been below expectations to date, this pricing shift may be as much a correction of a prior pricing error as it is a reflection of support scheme eligibility requirements. If so, at least the correction is now being made and the company giving itself a chance to move more units.

All up this should be a very positive development for sales volumes, offset somewhat by the material price reduction. With the delayed rollout it looks like it may have a reasonable impact on Life volumes and sales from FY22, at least in Australia.

Expand

@cad1llac I think the quoted price is after Govt subsidy.

SPA Price at posting: 16.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ASX Market Open: Aussie stocks to open lower despite positive performances for US bourses | October 1, 2024

The iron ore comeback: Can it last?

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 28 more messages in this thread...

First 9 Last

Add SPA (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $12.02M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
4	1600000	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.3¢	2119009	3

View Market Depth

No.	Vol.	Price($)
6	2100000	0.023
1	231721	0.022
3	295238	0.021
4	1250000	0.020
1	30000	0.019

Price($)	Vol.	No.
0.023	2119009	3
0.025	534616	2
0.026	43478	1
0.028	329910	2
0.029	290835	1

Last trade - 16.12pm 30/09/2024 (20 minute delay)

SPA (ASX) Chart

Day chart unavailable